Phase I study of sorafenib combined with radiation therapy and temozolomide as first-line treatment of high-grade glioma

Mostrar otras versiones (1)

BACKGROUND: Sorafenib (Sb) is a multiple kinase inhibitor targeting both tumour cell proliferation and angiogenesis that may further act as a potent radiosensitizer by arresting cells in the most radiosensitive cell cycle phase. This phase I open-label, noncontrolled dose escalation study was perfor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hottinger, A F, Aissa, A B, Espeli, V, Squiban, D, Dunkel, N, Vargas, M I, Hundsberger, T, Mach, N, Schaller, K, Weber, D C, Bodmer, A, Dietrich, P-Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037825/
https://www.ncbi.nlm.nih.gov/pubmed/24786603
http://dx.doi.org/10.1038/bjc.2014.209

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4037825/
https://www.ncbi.nlm.nih.gov/pubmed/24786603
http://dx.doi.org/10.1038/bjc.2014.209

Ejemplares similares